Frequency of Concurrent Use of Warfarin with Potentially Interacting Drugs
- 1 December 2004
- journal article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 24 (12), 1668-1674
- https://doi.org/10.1592/phco.24.17.1668.52338
Abstract
To determine the rates of concomitant use of drugs known to interact with warfarin by increasing the prothrombin time expressed as the international normalized ratio (INR), decreasing the INR, or increasing bleeding risk without apparent changes in INR in a cohort of patients receiving long-term warfarin therapy. Retrospective, longitudinal cohort study. Large pharmacy benefits manager database. A total of 134,833 patients who were prescribed long-term warfarin from June 1, 1999-May 31, 2000. Longitudinal pharmacy claims from the pharmacy benefits manager database were reviewed to identify coprescription of warfarin and drugs associated with significant interactions with warfarin. Of the 134,833 patients receiving long-term warfarin therapy, 109,998 (81.6%) were prescribed a concurrent prescription for at least one potentially interacting drug, including 87,346 (64.8%) who were prescribed one or more concomitant drugs associated with interactions known to increase the INR. Acetaminophen-containing products, prescribed for 22.7% of patients receiving concomitant prescriptions, and thyroid hormones, prescribed for 17.5%, were the most commonly prescribed concurrent drugs associated with an increased INR response. The most frequently prescribed interacting agents associated with a decreased INR response were trazodone (2.2%) and carbamazepine (1.1%). The most commonly prescribed agents independently associated with increased bleeding risk were cyclooxygenase-2 inhibitors. Many patients receiving warfarin therapy are treated with concomitant drugs that may interact with the warfarin. The high percentage of patients taking drugs that may increase INR or bleeding risk is a reminder that bleeding events are a likely adverse outcome of combining drugs that interact with warfarin. Careful warfarin management is necessary to avoid adverse events associated with drug interactions.This publication has 15 references indexed in Scilit:
- Multivitamin Supplements May Affect Warfarin Anticoagulation in Susceptible PatientsAnnals of Pharmacotherapy, 2003
- Incidence and Preventability of Adverse Drug Events Among Older Persons in the Ambulatory SettingPublished by American Medical Association (AMA) ,2003
- Drug Interactions in At-risk Emergency Department PatientsAcademic Emergency Medicine, 2002
- Drug Interactions in At‐risk Emergency Department PatientsAcademic Emergency Medicine, 2002
- The nature and frequency of potential warfarin drug interactions that increase the risk of bleeding in patients with atrial fibrillationPharmacoepidemiology and Drug Safety, 2002
- Use of medications and polypharmacy are increasing among the elderlyJournal of Clinical Epidemiology, 2002
- Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trialAmerican Journal Of Medicine, 2002
- Recent Patterns of Medication Use in the Ambulatory Adult Population of the United StatesJAMA, 2002
- An Analysis of the Lowest Effective Intensity of Prophylactic Anticoagulation for Patients with Nonrheumatic Atrial FibrillationNew England Journal of Medicine, 1996
- Risk Factors for Intracranial Hemorrhage in Outpatients Taking WarfarinAnnals of Internal Medicine, 1994